Relación entre los anticuerpos contra antígenos extraíbles del núcleo y las enfermedades del tejido conectivo identificados por Immunoblots en un hospital y universidad de Lima

José Enrique  Oliva Menacho; Jorge Luis  Arroyo Acevedo; Jose Arturo  Oliva Candela; Percy Genaro  Salas Ponce; Marco Antonio  Garcia Hjarles

doi:10.47196/rar.v31i2.405

José Enrique Oliva Menacho Hospital Nacional Arzobispo Loayza, Lima, Perú
Jorge Luis Arroyo Acevedo Universidad Nacional Mayor de San Marcos, Lima, Perú
Jose Arturo Oliva Candela Hospital Nacional Arzobispo Loayza, Lima, Perú
Percy Genaro Salas Ponce Hospital Nacional Arzobispo Loayza, Lima, Perú
Marco Antonio Garcia Hjarles Hospital Nacional Arzobispo Loayza, Lima, Perú

DOI: https://doi.org/10.47196/rar.v31i2.405

Palabras clave: anticuerpos contra antígenos del núcleo extraíbles, Immunoblots, enfermedades autoinmunes, Perú. (Fuente: MeSH NLM)

Resumen

Objetivos: determinar la relación de los anticuerpos con los antígenos del núcleo extraíble y las enfermedades del tejido conectivo identificadas por Immunoblot en un hospital de Lima, Perú. Material y métodos: estudio de tipo observacional, ciencias básicas, analíticas y transversales, realizado en el Servicio de Inmunología del Hospital Nacional Arzobispo Loayza entre enero de 2018 y junio de 2018. Analizamos 291 historias clínicas de pacientes con enferme-dad del tejido conectivo y para la detección de anticuerpos contra los antígenos extraíbles del núcleo se empleó el método de Immunoblots.

Biografía del autor/a

Marco Antonio Garcia Hjarles, Hospital Nacional Arzobispo Loayza, Lima, Perú

Facultad de Ciencias y Filosofía

Citas

I. Kumar S, Aggarwa A. Approach to a patient with connective tissue disease. The Indian Journal of Pediatrics. 2010;77(10): 1157-1164.

II. Abumohor P. Enfermedades del tejido conectivo: importancia del diagnóstico precoz. Revista Médica de Clínica Las Condes. 2012; 23(4): 391-400.

III. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and patholo-gical roles of Ro/SSA autoantibody system. Clinical and Develop-mental Immunology. 2012; 2012(1):1-12.

IV. Xue D, Shi H, Smith JD, Chen X, Noe DA, Cedervall T, et al. A lu-pus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proceedings of the National Academy of Sciences. 2003;100(13):7503-8.

V. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and an-ti-RNP antibodies. Autoimmunity. 2005;38(1):47-54.

VI. Agarwal S, Harper J, Kiely PDW. Concentration of antibodies to ex-tractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus. 2009;18(5):407-12.

VII. Kurien BT, Scofield RH. Autoantibody Determination in the Diag-nosis of Systemic Lupus Erythematosus. Scandinavian Journal of Immunology. 2006;64(3):227-35.

VIII. Kvarnstrom M, Dzikaite-Ottosson V, Ottosson L, Gustafsson JT, Gunnarsson I, Svenungsson E et al. Autoantibodies to the functio-nally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus. Lupus. 2013;22(5):477-85.

IX. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatology. 1982;25(11):1271-7.

X. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Co-llaborating Clinics classification criteria for systemic lupus erythe-matosus. Arthritis Rheumatology. 2012;64(8):2677-86.

XI. Egner W. The use of laboratory tests in the diagnosis of SLE. Journal of Clinical Pathology. 2000;53(6):424-432.

XII. Martinez-Cordero E, Martinez-Miranda E, Negrete-Garcia MC, Padi-lla A, Aguilar Leon DE. Anti-dsDNA and Sm autoantibodies in sys-temic lupus erythematosus. Clinical Rheumatology. 1992;11(3):341-345.

XIII. Agarwal S, Harper J, Kiely P. Concentration of antibodies to ex-tractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus. 2009;18(5):407-12.

XIV. 14. Gussin H, Ignat G, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythema-tosus. Arthritis Rheumatology. 2001;44(2):376-383.

XV. Albon S, Bunn C, Swana G. Performance of a multiplex assay com-pared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. Journal of Immunologi-cal Methods. 2011;365(1-2): 126-131.

XVI. Ghedira, I., Landolsi, H., & Mankai, A. Antihistones antibodies in systemic lupus erythematosus, comparison of three assays: elisa, dot blot and immunoblot. Pathologie Biologie. 2006; 54(3): 148-154.

XVII. Albon S, Bunn C, Swana G. Performance of a multiplex assay com-pared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. Journal of Immunologi-cal Methods. 2011; 365(1-2):126-131.

XVIII. Schulte J, Fritzler M, Mahler M. Latest update on the Ro/SS-A au-toantibody system. Autoimmunity Reviews. 2009; 8(7): 632-637.

XIX. Catoggio L, Bernstein R, Black C. Serological markers in progressive systemic sclerosis: clinical correlations. Annals of the Rheumatic Diseases.1983.42(1): 23-27.

XX. Shinjo S, Levy-Neto M. Anti-Jo-1 antisynthetase syndrome. Revista Brasileira de Reumatología. 2010. 50(5): 492-500.

XXI. Tozzoli R, Bizzarro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody test in the diag-nosis and monitoring of autoimmune rheumatic diseases. Ameri-can Journal of Clinical Pathology. 2002;117(2):316-24.

XXII. Severiche D, Escobar M, Naranjo L, García A, Vahos C, Duque G. Ciento quince pacientes con lupus eritematoso sistémico: Carac-terísticas clínicas e inmunológicas. Revista Colombiana de Reuma-tologia.2004;21(4):183-92.

XXIII. Aggarwal A. Role of autoantibody testing. Best Practice & Research Clinical Rheumatology. 2014; 28(6): 907–20.

XXIV. Mierendorf S, Shmerling RH. Antinuclear antibody testing. Hosp Med Clin. 2012;1: 370–7.

XXV. Manoussakis M, Kistis K, Liu X, Aidinis V, Guialis A, Moutsopoulos H. Detection of anti-Ro (SSA) antibodies in autoimmune diseases: comparison of five methods. British J Rheumatol.1993; 32(6): 449-455.

XXVI. Reichlin M and Scofield RH. SSA(Ro) autoantibodies. En: James B. Peter and Yehuda Shoenfeld eds. Autoantibodies. Elsevier, 1996.

XXVII. Tzioufas A, Moutsopoulos H. Clinical significance of autoantibo-dies to Ro/SSA and La/SSB. En: van Venrooij WJ and Maini RN eds. Manual of Biological Markers of Diseases. Kluwer Academic Publi-shers, 1996.

XXVIII. Wahren M, Téngner P, Gunnarsson I, Lundberg I, Hedfors E, Rin-gertz NR, Pettersson I. Ro/SS-A and La/SS-B antibody level va-riation in patients with Sjogren’s syndrome and systemic lupus erythematosus. J Autoimmun 1998;11(1):29-38.

XXIX. Boire G, Gendron M, Monast N, Bastin B, Menard H. Purification of antigenically intact Ro ribonucleoproteins; biochemical and im-munological evidence that the 52-kD protein is not a Ro protein. Clinical and experimental Immunology.1995;100(3):489-498.

XXX. Le Roy EC, Black C, Fleischmajer R. Scleroderma (systemic sclero-sis): Classification subsets and pathogenesis. J. Rheumatol. 1980; 15(2):202-205.

XXXI. Hanke K, Uibel S, Bruckner C, Dahnrich C, Egerer K, Hiepe F, Schu-lumberger W, Riemekasten G. An-tibodies to CENP – B antigen identify a subgroup of systemic sclerosis patients presenting more frequently sicca syndrome and less frequently lung fibrosis, car-diac and vascular involvement- analysis of the Charite SSc cohort. En: Conrad K et al. (Hrsg.). From Etiopathogenesis to the predic-tion of autoimmune diseases: Relevance of Autoantibodies. Pabst Science Publisher ;5(2007): 477-478.